File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Comparison of two plasma-derived hepatitis B vaccines: Long-term report of a prospective, randomized trial

TitleComparison of two plasma-derived hepatitis B vaccines: Long-term report of a prospective, randomized trial
Authors
Issue Date1989
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH
Citation
Journal Of Gastroenterology And Hepatology, 1989, v. 4 n. 4, p. 331-337 How to Cite?
AbstractSubjects at high risk for hepatitis B (HBV) infection were allocated randomly (n=591) to receive one of the two plasma-derived hepatitis B vaccines produced by the Institut Pasteur Production, Paris (HEVAC B) or the Green Cross Corporation, Osaka (GCC VAC). There are differences in the production of these two vaccines, with an added step of heat inactivation and longer formaldehyde treatment for the GCC VAC. Three doses of vaccines were given at 0, 1, and 5 months for both vaccines. Antibody to hepatitis B surface antigen (anti-HBs) titres were tested at 1, 3, 6, 9, 12, 18, 24 months. Antibody to hepatitis B core antigen (anti-HBc) was tested at 6 and 24 months. A fourth dose was given after 12 months to subjects who did not develop an anti-HBs titre of 10 miu/mL at month 6. Two hundred and seventy-four subjects received HEVAC B. Excluding nine subjects (3.4%) who became positive for anti-HBc, the immunogenicity was 87.2%. For the 317 subjects receiving GCC VAC, excluding 17 subjects (5.4%) who became positive for anti-HBc, the immunogenicity was 83.7% (the difference was not statistically significant). The anti-HBs titres were significantly higher in those who received HEVAC B in the 3, 6, 9, 12 and 18 months but the anti-HBs levels for GCC VAC recipients were still well above the 'protective' level of 10 miu/mL. Most hypo/non-responders did not respond to the fourth dose of vaccine. The side-effects were transient and mild, and occurred in 1.5% of subjects for both vaccines. Anti-HBs response decreased significantly with increasing age of the recipients. It is concluded that both HEVAC B and GCC VAC had comparable immunogenicity and safety, although GCC VAC gave a significantly lower but still 'protective' anti-HBs level at 3-18 months. This might be related to the added steps of inactivation in its production
Persistent Identifierhttp://hdl.handle.net/10722/161777
ISSN
2015 Impact Factor: 3.322
2015 SCImago Journal Rankings: 1.190
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLau, JYNen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorWu, PCen_US
dc.contributor.authorLin, HJen_US
dc.date.accessioned2012-09-05T05:14:52Z-
dc.date.available2012-09-05T05:14:52Z-
dc.date.issued1989en_US
dc.identifier.citationJournal Of Gastroenterology And Hepatology, 1989, v. 4 n. 4, p. 331-337en_US
dc.identifier.issn0815-9319en_US
dc.identifier.urihttp://hdl.handle.net/10722/161777-
dc.description.abstractSubjects at high risk for hepatitis B (HBV) infection were allocated randomly (n=591) to receive one of the two plasma-derived hepatitis B vaccines produced by the Institut Pasteur Production, Paris (HEVAC B) or the Green Cross Corporation, Osaka (GCC VAC). There are differences in the production of these two vaccines, with an added step of heat inactivation and longer formaldehyde treatment for the GCC VAC. Three doses of vaccines were given at 0, 1, and 5 months for both vaccines. Antibody to hepatitis B surface antigen (anti-HBs) titres were tested at 1, 3, 6, 9, 12, 18, 24 months. Antibody to hepatitis B core antigen (anti-HBc) was tested at 6 and 24 months. A fourth dose was given after 12 months to subjects who did not develop an anti-HBs titre of 10 miu/mL at month 6. Two hundred and seventy-four subjects received HEVAC B. Excluding nine subjects (3.4%) who became positive for anti-HBc, the immunogenicity was 87.2%. For the 317 subjects receiving GCC VAC, excluding 17 subjects (5.4%) who became positive for anti-HBc, the immunogenicity was 83.7% (the difference was not statistically significant). The anti-HBs titres were significantly higher in those who received HEVAC B in the 3, 6, 9, 12 and 18 months but the anti-HBs levels for GCC VAC recipients were still well above the 'protective' level of 10 miu/mL. Most hypo/non-responders did not respond to the fourth dose of vaccine. The side-effects were transient and mild, and occurred in 1.5% of subjects for both vaccines. Anti-HBs response decreased significantly with increasing age of the recipients. It is concluded that both HEVAC B and GCC VAC had comparable immunogenicity and safety, although GCC VAC gave a significantly lower but still 'protective' anti-HBs level at 3-18 months. This might be related to the added steps of inactivation in its productionen_US
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGHen_US
dc.relation.ispartofJournal of Gastroenterology and Hepatologyen_US
dc.subject.meshAdulten_US
dc.subject.meshFemaleen_US
dc.subject.meshHepatitis B - Epidemiology - Prevention & Controlen_US
dc.subject.meshHepatitis B Vaccinesen_US
dc.subject.meshHong Kong - Epidemiologyen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunization Scheduleen_US
dc.subject.meshMaleen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshRisk Factorsen_US
dc.subject.meshVaccines, Syntheticen_US
dc.subject.meshViral Hepatitis Vaccinesen_US
dc.titleComparison of two plasma-derived hepatitis B vaccines: Long-term report of a prospective, randomized trialen_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1440-1746.1989.tb00844.x-
dc.identifier.pmid2535239-
dc.identifier.scopuseid_2-s2.0-0024392830en_US
dc.identifier.volume4en_US
dc.identifier.issue4en_US
dc.identifier.spage331en_US
dc.identifier.epage337en_US
dc.identifier.isiWOS:A1989AM30000005-
dc.publisher.placeAustraliaen_US
dc.identifier.scopusauthoridLau, JYN=7402446047en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridWu, PC=7403119323en_US
dc.identifier.scopusauthoridLin, HJ=7405571292en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats